The Cigna Group stock: RBC lifts target to $346
Published on 11/21/2026 at 10:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRBC raises Cigna price target
- RBC linked its more positive view to a third-quarter earnings beat and stronger Cigna Healthcare performance.
- Pharmacy Benefit Services headwinds remain central to the 2027 outlook.
- Management expressed confidence in at least 10% adjusted earnings-per-share growth from an adjusted base near 30 US dollars.
On Thursday, November 19, RBC Capital raised its price target for The Cigna Group from 337 to 346 US dollars and kept an Outperform rating. Fidelity, carrying an MT Newswires report, said the third-quarter beat reflected solid performance in Cigna Healthcare and continued momentum in Specialty and Care Services.
Healthcare strength meets pharmacy risks
RBC said management remained confident in delivering at least 10% adjusted earnings-per-share growth from an adjusted base of about 30 US dollars. The analysts raised their 2026 adjusted earnings-per-share estimate to 30.66 US dollars from 30.49 US dollars.
The research note also lowered RBC's 2027 adjusted earnings-per-share estimate to 33.04 US dollars from 33.53 US dollars. The cited pressures include stranded overhead after the Affordable Care Act exchange exit, softer Evernorth margins, smaller rebate pools and lower employer coverage of GLP-1 weight-loss drugs.
Saturday trading remains in focus
The Cigna Group stock traded at 247.00 euros on Lang & Schwarz at 10:54 CET on Saturday, November 21.
The Cigna Group stock at a glance
- Company: The Cigna Group
- ISIN: US1255231003
- Lang & Schwarz quote: 247.00 euros at 10:54 CET on November 21, 2026
- RBC rating: Outperform
Healthcare stocks remain sensitive to expectations for medical costs, pharmacy-benefit margins and government policy. Current market reports provide the broader market setting.
